Division of Neuroscience, Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.
BMC Psychiatry. 2014 Apr 8;14:104. doi: 10.1186/1471-244X-14-104.
It is assumed within the accumulated literature that children born of pregnant opioid dependent mothers have impaired neurobehavioral function as a consequence of chronic intrauterine opioid use.
Quantitative and systematic review of the literature on the consequences of chronic maternal opioid use during pregnancy on neurobehavioral function of children was conducted using the Meta-analysis of Observational Studies in Epidemiology (MOOSE) and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. We searched Cinahl, EMBASE, PsychINFO and MEDLINE between the periods of January 1995 to January 2012.
There were only 5 studies out of the 200 identified that quantitatively reported on neurobehavioral function of children after maternal opioid use during pregnancy. All 5 were case control studies with the number of exposed subjects within the studies ranging from 33-143 and 45-85 for the controls. This meta-analysis showed no significant impairments, at a non-conservative significance level of p < 0.05, for cognitive, psychomotor or observed behavioural outcomes for chronic intra-uterine exposed infants and pre-school children compared to non-exposed infants and children. However, all domains suggested a trend to poor outcomes in infants/children of opioid using mothers. The magnitude of all possible effects was small according to Cohen's benchmark criteria.
Chronic intra-uterine opioid exposed infants and pre-school children experienced no significant impairment in neurobehavioral outcomes when compared to non-exposed peers, although in all domains there was a trend to poorer outcomes. The findings of this review are limited by the small number of studies analysed, the heterogenous populations and small numbers within the individual studies. Longitudinal studies are needed to determine if any neuropsychological impairments appear after the age of 5 years and to help investigate further the role of environmental risk factors on the effect of 'core' phenotypes.
在已有的文献中,人们认为,由于胎儿在子宫内长期接触阿片类药物,孕妇所生的儿童会出现神经行为功能受损的情况。
根据荟萃观察性研究的流行病学(MOOSE)和系统评价和荟萃分析的首选报告项目(PRISMA)指南,对有关母亲在怀孕期间长期使用阿片类药物对儿童神经行为功能影响的文献进行了定量和系统评价。我们在 Cinahl、EMBASE、PsychINFO 和 MEDLINE 数据库中检索了 1995 年 1 月至 2012 年 1 月期间的文献。
在所鉴定的 200 篇文献中,仅有 5 篇定量报道了母亲在怀孕期间使用阿片类药物后儿童的神经行为功能。这 5 项研究均为病例对照研究,研究中暴露组的研究对象数量为 33-143 例,对照组为 45-85 例。本荟萃分析显示,与未暴露组相比,慢性宫内暴露的婴儿和学龄前儿童在认知、精神运动或观察到的行为结果方面没有显著受损,非保守显著性水平为 p<0.05。然而,所有领域都表明,阿片类药物使用母亲的婴儿/儿童的结果较差。根据科恩的基准标准,所有可能的影响的幅度都很小。
与未暴露于阿片类药物的同龄人相比,慢性宫内暴露的婴儿和学龄前儿童的神经行为发育结果没有明显受损,但在所有领域都存在结果较差的趋势。本综述的研究结果受到分析的研究数量有限、人群异质性和个别研究中数量较少的限制。需要进行纵向研究,以确定 5 岁后是否会出现任何神经心理损伤,并进一步研究环境危险因素对“核心”表型的影响。